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Purpose: The prognosis of patients with malignant pheochromocytoma is poor, but the 
predictive factors are not well understood. We aimed to identify the clinical character-
istics predictive of malignancy after initial surgical removal in patients with pheo-
chromocytoma. 
Materials and Methods: We retrospectively reviewed the records of 152 patients diag-
nosed with pheochromocytoma, including 5 (3.3%) with metastasis at the time of the 
initial surgical excision and 12 (7.9%) who developed metastasis during follow-up. To 
determine the factors predictive of malignancy, we compared clinical, radiographical, 
and urinary chemical findings between patients with benign and malignant disease. 
Mean follow-up was 41.5 months (range, 0.9-298 months) after surgery.
Results: Malignant tumors were significantly larger than benign tumors (11.1±4.0 cm 
vs. 6.2±3.4 cm, p＜0.001), and postoperative persistence of arterial hypertension was 
more frequent after removal of malignant than benign tumors (p=0.001). Among the 
147 patients without metastatic disease at diagnosis, those who developed metastasis 
had significantly lower concentrations of urinary catecholamine metabolites per unit 
of tumor, including vanillylmandelic acid (1.2 vs. 3.7 mg/day/cm, p=0.049), epinephrine 
(4.5 vs. 168.9 μg/day/cm, p=0.008), and norepinephrine (13.1 vs. 121.8 mg/day/cm, p
＜0.001). The overall 5-year metastasis-free survival rate was 84.4% and was sig-
nificantly higher in patients with smaller tumors (≤5.5 vs. ＞5.5 cm; 90.6% vs. 81.2%, 
p=0.025) and higher 24-hour secretion of vanillylmandelic acid (＞2.1 vs. ≤2.1 mg/ 
day/cm; 94.9% vs. 70.9%, p=0.019). 
Conclusions: Large tumor size (＞5.5 cm) and minimally elevated 24-hour urinary va-
nillylmandelic acid (≤2.1 mg/day/cm) were significantly associated with a higher prob-
ability of a malignant pheochromocytoma portending a lower metastasis-free survival 
and mandating more rigorous follow-up after surgery.
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Pheochromocytoma is a catecholamine-secreting tumor 
that emerges from the chromaffin cells of the adrenal me-
dulla, usually manifesting as a benign tumor but occasion-
ally becoming malignant [1,2]. Because the long-term prog-
nosis of patients with malignant pheochromocytoma is un-
clear or poor, identification of factors associated with ma-
lignancy could aid in modifying follow-up plans and could 
enhance disease-specific survival. Previous studies on ma-
lignant pheochromocytoma have mostly been anecdotal, 
and efforts to clinically, biochemically, and radiogra-
phically distinguish between benign and malignant pheo-
chromocytoma have been inconsistent [3,4]. Partly, these 
may have been because of the low incidence of the tumor 
and the limited postoperative follow-up with inconsistent Korean J Urol 2011;52:241-246
242 Park et al
TABLE 1. Comparison of clinical characteristics of patients with
benign and malignant pheochromocytomas
Benign Malignant p-value
No. of patients 135 17
Age (yr)  46.6 (18-76)     45.4 (18-65) 0.588
Sex (male:female) 1.2:1 (73:62) 0.9:1 (8:9) 0.832
Hypertension (%) 87 (64)      7 (41) 0.110
Postoperative hypertension   1 (0.7)         4 (23.5) 0.001
 (%)
Primary tumor size (cm)   6.2±3.4 11.1±4.0 ＜0.001
Extra-adrenal location (%) 11 (8)   4 (24) 0.068
Bilaterality (%)   7 (5) 1 (6) 1.000
24-hr urine VMA (mg/day)
a 21.4±2.5 21.5±7.8 0.810
24-hr urine epinephrine   487.0±179.5 16.1±8.4 0.083
 (μg/day)
a
24-hr urine norepinephrine  625.0±147.2   327.0±205.4 0.488
 (μg/day)
a
24-hr urine metanephrine   7.8±2.3   5.4±2.3 0.798
 (mg/day)
a
24-hr urine dopamine 212.7±34.9   433.0±104.5 0.083
 (μg/day)
a
VMA: vanillylmandelic acid, 
a: mean±SE
protocols. Therefore, from a single institutional database, 
we aimed to identify potential clinical characteristics pre-
dictive of differentiating malignant pheochromocytomas 
from benign pheochromocytomas.
MATERIALS AND METHODS
Our study consisted of 152 patients treated surgically be-
tween 1989 and 2008 at our hospital. The 152 patients con-
sisted of 81 men and 71 women, aged 18 to 76 years (median, 
46.5 years). Of these, 135 had benign tumors and 17 had 
malignant tumors (5 at the initial diagnosis and 12 sub-
sequently diagnosed during follow-up). The clinical diag-
nosis of malignancy in the 17 patients was based on the 
presence of metastatic lesions either at diagnosis or during 
follow-up.
　Preoperatively, tumors were localized by computed to-
mography (CT) and/or magnetic resonance imaging (MRI). 
Also, metaiodobenzylguanidine-131 (MIBG) scans were 
performed in patients with suspected extra-adrenal or ma-
lignant pheochromocytoma. Twenty-four-hour urinary 
concentrations of vanillylmandelic acid (VMA), epine-
phrine, norepinephrine, metanephrine, and dopamine 
were assessed in most patients. Postoperative follow-up in-
cluded blood pressure measurement, CT, and MIBG scan 
every 6 months for 2 years and annually thereafter in the 
absence of recurrence. Urinary catecholamines were fol-
lowed when elevated levels were observed at 6 months 
postoperatively. Patients were followed for a mean of 41.5 
months (range, 0.9-298 months) after surgery. 
　Factors compared between the two groups included clin-
ical (age, gender, symptoms, interval to diagnosis from 
symptom onset, associated syndromes, postoperative hy-
pertension), radiographical (tumor location, tumor size), 
and biochemical (urinary catecholamine levels) variables. 
The 24-hour urinary catecholamine levels per unit diame-
ter of tumor were calculated to account for the differences 
in tumor size. 
    For statistical analyses, we used the chi-squared test 
and the Mann-Whitney U test for comparison between the 
benign and the malignant characteristics. Cutoff values for 
tumor size and VMA per unit of tumor diameter were calcu-
lated by receiver operating characteristic (ROC) analysis 
for predicting the 5-year metastasis-free survival rate. 
Survival curves were determined by using the Kaplan- 
Meier method and were compared by the log-rank test. For 
all analyses, SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) 
was used, and a p-value＜0.05 was set for significance. 
RESULTS
There were 17 patients with metastatic pheochromo-
cytomas. Initially metastatic lesions (n=5) were found in 
the lung (2), liver (1), bone (1), and distant lymph node (1). 
Metachronous metastases occurred on average 49.4 
months (range, 5.9-194.8 months) postoperatively. The lo-
cations of recurrent disease were liver (6), bone (4), lung 
and pleura (4), and bladder (1). Patients were diagnosed 
with pheochromocytoma, either benign or malignant, 
within 0.02 months to 7.2 years (median, 1.8 years) from 
the onset of symptoms. Familial syndromes, including von 
Hippel-Lindau syndrome, were present in three patients 
with benign tumors but in none of those with malignancies. 
Of the 152 tumors, 137 (90.1%) were adrenal, 14 (9.2%) 
were solitary extra-adrenal, and 1 (0.7%) was multiple ex-
tra-adrenal. In particular, 11 (8%) of the 135 benign tumors 
were extra-adrenal, compared with 4 (24%) of the 17 malig-
nant tumors. The single multiple extra-adrenal tumor was 
malignant, whereas the seven bilateral adrenal tumors 
were benign. Of the extra-adrenal pheochromocytomas, 
two malignant and five benign tumors were located in the 
periaortic (Zuckerkandl) bodies, and the remainder were 
in the retroperitoneum, bladder, and other organs (Table 
1). 
　Malignant tumors were significantly larger than benign 
pheochromocytomas (11.1±4.0 vs. 6.2±3.4 cm, p＜0.001) 
(Table 1). However, age and gender showed no significant 
correlations with malignancy. In addition, the most fre-
quent symptoms in patients with both benign and malig-
nant pheochromocytomas were headache, palpitations, 
and excessive sweating, without differences between the 
groups. Whereas blood pressure generally became normal 
after adrenalectomy, arterial hypertension persisted after 
removal more frequently in malignant tumors (23.5% vs. 
0.7%, p=0.001). 
　Preoperatively, total 24-hour urinary excretion of the cat-
echolamines VMA, epinephrine, norepinephrine, meta-
nephrine, and dopamine was significantly enhanced in pa-
tients with both malignant and benign pheochromocyto-
mas, without differences between the groups (Table 1). Korean J Urol 2011;52:241-246
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FIG. 1. Comparison of 24-hour urinary catecholamine secretion in patients with benign and malignant pheochromocytomas (A: benign
vs. all cases malignant, B: benign vs. postoperative recurrent malignant).
However, when the urinary catecholamines excreted per 
unit of tumor were compared, patients with malignant tu-
mors excreted significantly lower amounts of epinephrine 
(4.0 vs. 168.9 μg/day/cm, p=0.010) than did patients with 
benign tumors (Fig. 1A). Furthermore, among the 147 pa-
tients without metastatic disease at the initial diagnosis, 
those who later developed metastasis also had sig-
nificantly reduced 24-hour urinary excretion of the cat-
echolamine metabolites VMA (1.2 vs. 3.7 mg/day/cm, p= 
0.049), epinephrine (4.5 vs. 168.9 μg/day/cm, p=0.008), and Korean J Urol 2011;52:241-246
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FIG. 2. Metastasis-free survival relative to tumor size (A) and 24-hour urinary secretion of VMA/unit of tumor diameter (B).
norepinephrine (13.1 vs. 121.8 mg/day/cm, p＜0.001) than 
did those with benign tumors (Fig. 1B). 
　The overall 5-year metastasis-free survival rate was 
84.4%. The areas under the ROC curves for predicting the 
5-year metastasis-free survival rate were 0.783 (95% CI: 
0.652-0.914) for tumor size and 0.767 (95% CI: 0.674-0.920) 
for VMA per unit of tumor diameter. The tumor size cutoff 
for prediction of survival rates was calculated to be 5.5 cm 
(sensitivity 86.7%, specificity 56.7%), and the VMA per unit 
of tumor diameter cutoff value was calculated to be 2.1 
mg/day/cm (sensitivity 85.5%, specificity 58.1%). Survival 
rates were significantly higher in patients with smaller tu-
mors (≤5.5 cm vs. ＞5.5 cm; 90.6 vs. 81.2%, p=0.025) and 
in those with higher 24-hour urinary VMA per unit of tumor 
diameter (＞2.1 vs. ≤2.1 mg/day/cm; 94.9 vs. 70.9%, p= 
0.019) (Fig. 2). The 5-year survival rate of patients with ma-
lignant pheochromocytoma was 11.8%. Among patients 
with malignant disease, 1 patient received palliative radio-
therapy and 5 received palliative MIBG therapy, resulting 
in modulation of the symptoms of catecholamine hyper-
production. Although six patients received palliative com-
bined chemotherapy (cyclophosphamide/adriamycin), 
none demonstrated response to any chemotherapeutic 
agents and all progressed.
DISCUSSION
Clinical behavior, including invasion of adjacent tissues 
and the presence of metastases at non-chromaffin sites, is 
the only currently accepted indication of malignant pheo-
chromocytoma [5,6]. We found that the incidence of malig-
nant pheochromocytomas among 152 patients with pheo-
chromocytomas was 11.2%, in good agreement with the 8% 
to 12.5% previously reported [7-11]. We also found that the 
5-year survival rate of our patients with malignant pheo-
chromocytoma was 11.8%, which was thus somewhat low-
er than the 20% previously reported [12]. Although none 
of our patients with malignant pheochromocytomas were 
alive after 10 years, others have reported somewhat better 
results [2]. The poor prognosis of patients with malignancy 
is thought to be attributable to dissemination to other or-
gans, along with the heart failure associated with hyper-
catecholaminemia [6,13-18]. Thus, long-term prognosis 
will not improve unless other features that can predict ma-
lignant behavior can be identified. 
　Previous studies have not been successful in identifying 
distinctive factors for malignant pheochromocytoma. 
Although some histopathological features have been sug-
gested to be associated with an increased incidence of ma-
lignancy, including tumor necrosis, mitosis rate ＞3/30 
HPF, capsular invasion, vascular invasion, large nests 
with central degeneration, a lack of hyaline globules, a high 
nuclear/cytoplasmic ratio, monotony of cytological pat-
tern, and spindle cell patterns [6,17,19], none of these dif-
ferences is sufficiently diagnostic. Moreover, molecular 
markers, including telomerase [20], inhibins, activins [21], 
endothelial Per-ARNT-Sim domain protein-1, vascular en-
dothelial growth factor, endothelin receptor type B [22], 
and cyclooxygenase [21], have been found to be significant 
but unreliable and not readily applicable for distinguish-
ing benign from malignant pheochromocytomas. More-
over, in assaying clinical parameters, we found that age, 
gender, symptoms, and delay in diagnosis did not correlate 
with the presence of either benign or malignant pheo-
chromocytoma. Although extra-adrenal tumor location 
was associated with malignancy to some extent, the rela-
tionship was not significant (p=0.068). 
　We found, however, that malignant tumors were sig-
nificantly larger than were benign tumors at presentation 
(11.1±4.0 vs. 6.2±3.4 cm, p＜0.001). Although similar re-
sults have been reported (median tumor size, 8 cm vs. 5.1 
cm, respectively), no cutoff values for size and weight were 
found to differentiate benign from malignant tumors [23]. 
In contrast, we found that the use of a size cutoff of 5.5 cm 
could distinguish 5-year metastasis-free survival rates in 
patients with benign and malignant tumors (90.6% vs. 
81.2%, p=0.025). In contrast with studies reporting that 
malignant tumors secrete more metanephrines than do be-Korean J Urol 2011;52:241-246
Predictive Characteristics of Malignant Pheochromocytoma 245
nign tumors [19,24,25], we found that the 24-hour urinary 
excretion per tumor diameter unit of the catecholamine 
metabolites VMA and epinephrine was significantly lower 
in patients with malignant tumors than in those with be-
nign tumors, whereas the total excretions were similar. In 
particular, patients without metastatic disease at diag-
nosis showed more distinct differences in the secretion of 
the urinary catecholamine metabolites VMA, epinephrine, 
norepinephrine, and metanephrine. Necrosis in the tumor 
center, especially in large tumors, has been suggested to 
account for lower secretion in hormone-producing tumors 
[26]. However, in our study, gross tumor necrosis was ob-
served in only 5 of the patients and our results demonstrate 
that the catecholamines produced per unit of tumor instead 
of the total mass were significantly lower. We speculate 
that tumors cells with malignant potential may intrinsi-
cally carry less functional capacity because of under- 
differentiation.
　In agreement with earlier studies, which showed that 
persistent postoperative arterial hypertension was more 
common in patients with malignant than benign pheochro-
mocytomas, we found that arterial hypertension persisted 
after tumor removal in 1 of 135 (0.7%) patients with benign 
tumors and in 4 of 17 (23.5%) with malignant pheochromo-
cytomas, likely due to occult metastasis. Monitoring arte-
rial blood pressure after successful surgery may provide a 
clue for potential development of subsequent metastasis. 
Postoperative metastasis or recurrence was observed 
within 4.2 years of surgical treatment in 9 of 12 patients 
(75%) with malignancy, with a median time from primary 
excision to metastasis of 16.8 months (range, 4.8-194.8 
months). These findings suggest that patients at risk 
should undergo more rigorous follow-up with the use of 
imaging modalities such as postoperative CT and MIBG 
scanning for at least 2 years and with the use of biochemical 
modalities such as low 24-hour urinary catecholamine ex-
cretion within 4 months after surgery. 
　The retrospective design of our study and the relatively 
small number of patients from a single institution limit the 
interpretation of our study results. Furthermore, in the 
urinary catecholamine analysis, although we noted a high-
er significance with epinephrine and norepinephrine, we 
suggested a cutoff for VMA because it is the most widely 
and specifically used index for diagnosing pheochromocy-
toma, and data were not available for some of the other 
indexes. Thus, the predictive characteristics identified 
here require confirmation in a larger, prospective, multi-
center study. In particular, further research on the long- 
term prognostic value of pre- and postoperative 24-hour 
urinary catecholamine excretion would seem worthwhile. 
CONCLUSIONS
In patients with pheochromocytoma, large tumor size (＞
5.5 cm) and minimally elevated 24-hour urinary VMA (≤
2.1 mg/day/cm) were significantly associated with a higher 
probability of the tumor being a malignancy, thus portend-
ing a lower metastasis-free survival. Thus, patients with 
these characteristics mandate more rigorous follow-up af-
ter surgery.
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